Back

Effects of CDR132L on cardiac structure and function in heart failure with preserved ejection fraction and left ventricular hypertrophy: the 8212-Preserved trial

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Echocardiographic evaluation of mechanisms in heart failure Heart Failure with Preserved Ejection Fraction (HFpEF) Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Professor Rudolf De Boer

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Ventricular remodeling phenotypes following intermittent levosimendan therapy in advanced heart failure
Doctor R. Fernandes Da Silva (Evora, PT)
Abstract
Presentation thumbnail
Left ventricular remodeling and fibrosis indices are strongly associated with soluble ST2 but not with NTproBNP in patients with HFrEF: a comparative analysis
Doctor A. Ntalianis (Athens, GR)
Abstract
Presentation thumbnail
A parsimonious echocardiography-based model for long-term mortality risk stratification in heart failure with preserved ejection fraction
Doctor L. Mi (Beijing, CN)
Abstract
Presentation thumbnail
The role of diastolic dysfunction in heart failure with reduced ejection fraction (HFrEF)
Professor E. Jones (Leuven, BE)
Abstract
Presentation thumbnail
Right atrial stiffness index predicts mortality in pulmonary hypertension when standard atrial metrics fail
Doctor A. Pearlman (Melbourne, AU)
Abstract

Access the full session

Session thumbnail
Echocardiographic evaluation of mechanisms in heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Mitral regurgitation, atrial fibrillation, and HFpEF: a three-headed dragon

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources